Lipoprotein (a) levels are elevated in psoriasis: An updated systematic review and meta-analysis

Table 2 Lipoprotein (a) levels in psoriasis patients and healthy controls

Ref.	Year	Psoriasis patients (n)	Psoriasis Lp(a) (mg/dL)	Controls (n)	Controls Lp(a) (mg/dL)	P value
Seçkin et al[14]	1994	32	13.8 ± 11.8	13	7.5 ± 8.9	NS
Jones et al[16]	2000	50	23.0 ± 20.1	50	21.8 ± 20.3	NS
Rocha-Pereira et al[15]	2001	48	63.8 ± 40.1	40	31.8 ± 18.1	< 0.001
Uyanik et al[17]	2002	72	27.4 ± 3.6	30	19.4 ± 4.5	< 0.01
Pietrzak et al[18]	2009	34	34.2 ± 23.6	26	21.9 ± 14.4	0.029
Coimbra et al[19]	2010	34	57.0 ± 49.7	37	34.9 ± 26.4	≤ 0.01
Asefi et al[23]	2012	100	19.2 ± 16.5	100	17.1 ± 17.0	NS
Ferretti et al[20]	2012	23	29.6 ± 18.3	25	12.8 ± 2.6	< 0.001
Oliviero et al[21]	2012	14	9.7	33	5.6	NS
Nemati et al[22]	2013	90	19.2 ± 16.5	90	17.1 ± 15.1	NS
Asefi et al[25]	2014	100	19.4 ± 16.9	100	17.1 ± 17.1	NS
Papagoras et al[24]	2014	56	12.5	71	13.5	NS
Sunitha et al[26]	2015	45	28.0 ± 9.1	45	20.8 ± 7.0	< 0.001
Sorokin et al[27]	2018	232	23.1 ± 19.4	20	14.7 ± 12.7	0.004
Wadhwa et al[28]	2019	132	12.6 ± 35.9	132	4.5 ± 4.0	< 0.001
Miao et al[29]	2019	222	19.0 ± 23.0	445	15.0 ± 19.0	0.028
Garshick et al[31]	2021	35	17.0 ± 14.0	15	9.0 ± 20.0	0.02
Wang et al[30]	2022	152	14.0 ± 17.5	152	12.5 ± 15.1	NS

Lp(a): Lipoprotein (a); NS: Not significant.